While outsourcing respondents currently hold mixed opinions on conducting hybrid trials (some traditional and some decentralized components), over two-thirds either currently use or plan to use them in the next two years. Respondents also anticipate that hybrid trials will make up a greater proportion of their studies two years from now. This is starkly illustrated in the bar graph below, where 14% of respondents currently—and 31% two years from now—use hybrid strategies for at least 40% of their trials.

Find more respondent data on hybrid trials, as well as user experiences with varied clinical development outsourcing models in our report Clinical Development Outsourcing Models (4th Ed.)

Originally published in Life Science Leader.

View File